Navigation Links
Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes

Four-month study detailing effects of treatment of HIV-positive

individuals with American Biotech Labs (ABL) ASAP 10 treatment indicates

significant improvement in the condition of the subjects after treatment;

in-vitro laboratory work shows that ABL nanosilver particles can block

entry of the virus into cells, "eventually destroying the virus"

ALPINE, UT, Aug. 29 /PRNewswire-FirstCall/ - American Biotech Labs, developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(TM), today announced that a preliminary study of the effect of the company's ASAP 10 treatment on HIV-positive individuals has been published in the first issue of the Journal of the Science of Healing Outcomes (JSHO; JSHO is a scholarly health journal that publishes compelling new medical research data and reports.

The study was conducted over four months with seven HIV-positive patients, each of whom was administered 15 ml of ABL ASAP 10 ppm (parts per million) four times daily. As a result of the ABL treatment, "Clinically, (the patients) were 100 percent fit and were feeling much better after the treatment period," said Dr. B.M. Hegde, world-renowned cardiologist and editor of JSHO.

During the course of the therapy, the patients experienced an average body weight gain of eight kilograms (17.6 pounds) and an average T-lymphocyte count increase of 180 per micro-liter (39.52 percent).

One of the study's most significant findings, said Hegde, was the effect of ABL ASAP on HIV, the AIDS-causing virus. "Our recent laboratory work of the effect of nano silver in vitro on the... virus did show that the nanosilver particles could bind to (HIV) and could potentially block the viral entry into cells, eventually destroying the virus."

Hegde added, "Now that we have the laboratory results of the drug's efficacy and safety, we are planning a large scale controlled study of the application to HIV positive individuals in the near future."

About American Biotech Labs

American Biotech Labs (ABL;, founded in 1998, utilizes patented processes and SilverSol Technology(TM) to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the U.S. EPA as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings. The company's products are sold worldwide at health food stores and by medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands and through a variety of private labels.

SOURCE Clifton Mining Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
8. Symmetry Medical Reports Preliminary Third Quarter Revenue
9. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):